LATEST PSYCHEDELICS STOCKS NEWS

LOI48 views6 min read

Mydecine Signs LOI with Maya to Co-Develop a Novel Prescription Digital Therapeutic Platform Aiming to Further Increase Safety, Efficacy, and Accessibility of Psychedelic-Assisted Treatments

Mydecine Innovations Group
DENVER, Dec. 22, 2021 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NF.F) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, announced today that the Company has signed an LOI (letter of intent) with Maya. Together, the t... Read More...
1086 views7 min read

Optimi Health Receives Dealers License Inspection and Introduces Quality Assurance Department

Optimi Health
VANCOUVER, British Columbia, Dec. 21, 2021 -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional as well as novel psychedelic compounds focused on the health and wellness sector, is pleased to announce a facility inspection under ... Read More...
M & A939 views12 min read

HAVN Life Enters into Definitive Agreement to Acquire Spore Life Sciences Inc.

HAVN Life Sciences
The Subscription-based Functional Mushroom Company has established a significant consumer base in the U.S. VANCOUVER, BC, Dec. 20, 2021 - Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the "Company" or "Havn Life"), a biotechnology company developing natural health products and innovative therapies to support central nervous... Read More...
Financials126 views7 min read

MINDCURE Announces Certification of HIPAA Compliance, Bringing iSTRYM Closer to Commercial Deployment in the Second Quarter of 2022

Mind Cure Health
VANCOUVER, BC, Dec. 16, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE"), a leader in advanced proprietary technology and research for psychedelics, announced today that the Company and its digital therapeutics technology, iSTRYM, have been certified as Health Insurance Portability and Accountability Act (HI... Read More...
623 views4 min read

New Wave Provides Update To Spin-out Of Way Of Will

New Wave Holdings
THIS NEWS RLEASE IS NOT FOR DISTRIBUTION IN THE UNITED STATES OR TO U.S. NEWS AGENCIES Toronto, Dec. 15, 2021 -- NEW WAVE HOLDINGS CORP. (the "Company" or "New Wave") (CSE: SPOR) (FWB: 0XM2) (OTCPK: TRMNF) an investment issuer that provides capital and support services, provides an update to its spin-out transaction (the “Spin-out Transa... Read More...
Joint Venture141 views8 min read

Allied Corp Partners with Trulife Distribution for the U.S. Health and Wellness Market

Allied
KELOWNA, British Columbia, Dec. 15, 2021 -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) is pleased to announce the signing of a non-exclusive national sales and distribution contract with Trulife Distribution.Under this agreement, TruLife agrees to distribute, market, and sell Allied’s three brands and products across the Unite... Read More...
753 views2 min read

Silo Pharma, Inc. Engages Donohoe Advisory to Assist with its Efforts to Obtain a Listing on a National Stock Exchange

Silo Pharma
Englewood Cliffs NJ, Dec. 14, 2021 -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, announced the engagement of Donohoe Advisory Associates LLC ("Donohoe") for consulting and advisory services in connection with the potential up-listing of Silo’s common s... Read More...
136 views5 min read

Field Trip Launches Site Management Organization (SMO) Services, Hires Stéphan Côté as Head of Quality

Field Trip Health
TORONTO, Dec. 14, 2021 -- Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, today announced the launch of its Site Management Organization Services (“SMO Services”). The SMO Services will enable companies and researchers developing psychedelic therapi... Read More...
119 views4 min read

Lobe Sciences Announces That Its Shares Will Trade on the OTCQB(R) Market in the United States

Lobe Sciences
Vancouver, British Columbia--(Newsfile Corp. - December 13, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") is pleased to announce that it has received approval from OTC Markets Group Inc. ("OTCM") for its shares to trade on the OTCQB®. Lobe Sciences' common stock will commence trading on the OTCQB under th... Read More...
1066 views8 min read

Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug Development and Technology Initiatives

Mydecine Innovations Group
DENVER, Dec. 09, 2021 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced it has entered into an agreement with an investor to complete a non-brokered priv... Read More...
Calendar1148 views7 min read

Allied Colombia Exceeds the 120th Employee Milestone in Its Company Growth Trajectory

Allied
KELOWNA, British Columbia, Dec. 09, 2021 -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) is pleased to announce a milestone in its company growth trajectory. Allied Colombia SAS, a wholly owned subsidiary of Allied Corp, has now exceeded 120 full time employees. Over the past two years, Allied has been on a continual growth traj... Read More...
Calendar1587 views6 min read

Delic Corp Announces Participation Details For January 2022 Investor Conferences

Delic Holdings
Matt Stang, Co-founder and CEO of Delic Corp, Will Present the Company's Strategic Outlook at HC Wainwright Bioconnect Virtual Conference Jan 10-13 and CEM's 8th Annual AlphaNorth Capital Conference Jan 21-23 VANCOUVER, BC, Dec. 9, 2021 - Delic Holdings Corp ("Delic") (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (Original Source), a leader in ne... Read More...
45 views5 min read

Cybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products Regulatory Agency for Lead Candidate CYB003 for the Treatment of Major Depressive Disorder and Alcohol Use Disorder

Cybin
TORONTO, December 08, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics™" is pleased to announce that it has confirmed a scientific advice meeting with the UK Medical and Healthcare Products Regulatory Agency ("MHRA... Read More...
144 views4 min read

Algernon Pharmaceuticals Completes Manufacturing of Psychedelic Drug DMT Appoints UK Stroke Experts for Phase 2

Algernon Pharmaceuticals
VANCOUVER, British Columbia, Dec. 08, 2021 -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPD) a clinical stage pharmaceutical development company is pleased to announce that it has completed the manufacturing of its clinical grade supply (“cGMP”) of AP-188 (“N,N-Dimethyltryptamine or ... Read More...
Calendar70 views4 min read

Bright Minds Biosciences to Present at the Stifel GMP 2nd Annual Future of Healthcare Conference

Bright Minds Biosciences
VANCOUVER, British Columbia, Dec. 06, 2021 -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Ian McDonald, Chief Executive Officer, will... Read More...
142 views0 min read

Entheon Biomedical Announces Participation in the Benzinga Global Small Cap Conference

Entheon Biomedical
Detroit, Michigan--(Newsfile Corp. - December 3, 2021) - Entheon Biomedical (CSE: ENBI) will be presenting at the Benzinga Global Small Cap Conference taking place on December 8-9, 2021. We invite our shareholders and all interested parties to explore investment opportunities within the global small cap space.Sign up to get a free spectat... Read More...
136 views1 min read

Eric Sprott Announces Holdings in Entheon Biomedical Corp., (Formerly, MPV Exploration Inc.)

Entheon Biomedical
Toronto, Ontario--(Newsfile Corp. - December 3, 2021) - Eric Sprott announces that, today, 600,000 common share purchase warrants (Warrants) of Entheon Biomedical Corp., (held by 2176423 Ontario Ltd., a corporation he beneficially owns) expired unexercised representing a decrease in holdings of approximately 4.2% of the outstanding common... Read More...
1096 views4 min read

Psyence to Present at the H.C Wainwright 2nd Annual Psychedelics Conference December 6

Psyence Group
TORONTO, Dec. 03, 2021 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that Psyence Chief Executive Officer, Neil Maresky, will be presenting at the virtual H.C. Wainwright ... Read More...
145 views5 min read

UPDATE — Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial

Revive Therapeutics
Expanding the potential of Bucillamine as an effective treatment for Omicron variant (B.1.1.529)Bucillamine shown to inhibit SARS-CoV-2 infection in vitro for the Delta variant (B.1.617.2)Adding inflammatory markers along with viral load testing to current Phase 3 clinical study for COVID-19 aiming to strengthen Bucillamine’s profile as b... Read More...
137 views5 min read

Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial

Revive Therapeutics
Expanding the potential of Bucillamine as an effective treatment for Omicron variant (B.1.1.529)Bucillamine shown to inhibit SARS-CoV-2 infection in vitro for the Delta variant (B.1.617.2)Adding inflammatory markers along with viral load testing to current Phase 3 clinical study for COVID-19 aiming to strengthen Bucillamine’s profile as b... Read More...
Capital Raise1172 views3 min read

Psyence Group Announces Private Placement

Psyence Group
TORONTO, Dec. 02, 2021 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it is commencing a non-brokered private placement offering of up to CAD$2,000,000 of unsecured convertible pro... Read More...
924 views7 min read

Psyence Group Functional Mushroom Brand “GOODMIND™” Commences National Roll-Out in South Africa’s Largest Coffee Retail Chain

Psyence Group
Company Broadens Revenue Generation InitiativesGOODMIND™Elevate your daily grind / GOODMIND™Elevate your daily grind / GOODMIND™TORONTO, Dec. 02, 2021 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-bein... Read More...
136 views8 min read

Ketamine Wellness Centers (KWC) Announces Plans to Expand Operations into Salt Lake City and Reno

Delic Holdings
KWC Expands to Include 12 Locations by Q1 2022, Further Establishing its Position as the Nation's Largest Chain of Wellness Clinics, Adds to Delic's Network of Locations VANCOUVER, BC, Dec. 2, 2021 - Delic Holdings Corp ("Delic") (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (Original Source), a leader in new medicines and treatments for a moder... Read More...
Joint Venture121 views4 min read

Novamind Partners with Uruguay-Based Bienstar Wellness to Develop Latin America’s First Integrative Mental Health Clinic Network

Novamind
Strategic investment and advisory agreement enables the global expansion of Novamind's psychedelic clinic modelTORONTO, ON / ACCESSWIRE / December 1, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind"), a leading mental health company specialized in psychedelic medicine, today announced a strategic investment and advisory agr... Read More...
42 views5 min read

Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases

Bright Minds Biosciences
— Hundreds of de novo patentable psychedelic-based compounds created through discovery program — — Company plans to announce lead molecule in first quarter of 2022 — VANCOUVER, British Columbia, Nov. 30, 2021 -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on... Read More...
Financials138 views4 min read

Psyence Group Inc. files Q2 Unaudited Condensed Consolidated Interim Financial Statements and MD&A

Psyence Group
TORONTO, Nov. 26, 2021 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company with a focus on natural psychedelics in mental health and well-being, announces that the Unaudited Condensed Consolidated Interim Financial Statements for the six months period ended September 30, 2021... Read More...





Make smarter investment strategies
with in-depth news reports

Join our subscribers!